KC1036

Phase 3Small molecule

BBeijing Konruns Pharmaceutical Co., Ltd.

KC1036 is one of 131 small molecule programs targeting Esophageal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

130

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerRecruiting

Ewing SarcomaRecruiting

Patients With Advanced Solid TumorsRecruiting

Thymic TumorsRecruiting

AdvancedRecruiting

Esophageal CancerPhase 3

Recruiting

Ewing SarcomaPhase 2

Recruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Thymic TumorsPhase 2

Recruiting

AdvancedPhase 2

Recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

19 2

Eloxatin

Teva

Phase 2

9 3

Tecentriq

Roche

Phase 2

4 4

Camptosar

Pfizer

Phase 2

4 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

15 6

Erbitux

IImclone

Phase 2

9 7

Tuoyi

CCoherus Oncology, Inc.

Phase 2

9 8

Lazcluze

Johnson & Johnson

Phase 2

1 9

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

6 10

KC1036

BBeijing Konruns Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Esophageal Cancer

NCT06194734

Q2 2028

Phase 2Recruiting

Ewing Sarcoma

NCT06564272

Q4 2028

Phase 2Recruiting

Esophageal Cancer

NCT07481058

Clinical

Trials by Indication[1]

Esophageal Cancer2 trials

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Recruiting·BBeijing Konruns Pharmaceutical Co., Ltd.·Phase 2·NCT07481058·60 enrolled

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

Recruiting·BBeijing Konruns Pharmaceutical Co., Ltd.·Phase 3·NCT06194734·490 enrolled

Thymic Tumors1 trial

A Study of KC1036 in Patients with Advanced Thymic Tumors

Recruiting·BBeijing Konruns Pharmaceutical Co., Ltd.·Phase 2·NCT05683886·30 enrolled

Ewing sarcoma1 trial

A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

Recruiting·BBeijing Konruns Pharmaceutical Co., Ltd.·Phase 2·NCT06564272·30 enrolled

Advanced1 trial

To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting·BBeijing Konruns Pharmaceutical Co., Ltd.·Phase 1/2·NCT05260385·133 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of KC1036 in Patients with Advanced Solid Tumors

Recruiting·BBeijing Konruns Pharmaceutical Co., Ltd.·Phase 1·NCT04387916·207 enrolled

1 more indication

Unspecified1 trial

A Food Effect Study of KC1036 in Healthy Subjects

Completed·BBeijing Konruns Pharmaceutical Co., Ltd.·N/A·NCT05265338·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for KC1036. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KC1036 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KC1036. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Konruns Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Konruns Pharmaceutical Co., Ltd.

KC1036

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Esophageal Cancer2 trials

Thymic Tumors1 trial

Ewing sarcoma1 trial

Advanced1 trial

Patients With Advanced Solid Tumors1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News